Management of Nephrotic Syndrome
The management of nephrotic syndrome requires a comprehensive approach targeting both the underlying disease with immunosuppression (when indicated) and the complications of proteinuria, edema, hyperlipidemia, hypertension, and thromboembolism through supportive measures.
Initial Assessment and Disease-Specific Treatment
The first priority is establishing whether nephrotic syndrome is primary (idiopathic) or secondary to systemic disease, which typically requires kidney biopsy 1, 2. The three main primary causes are minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy 1.
For Minimal Change Disease (Adults)
- Start prednisone 1 mg/kg/day (maximum 80 mg) or alternate-day 2 mg/kg (maximum 120 mg) 2
- Continue high-dose steroids for minimum 4 weeks if remission achieved, maximum 16 weeks if no remission 2
- Taper slowly over 6 months after achieving complete remission 2
- For steroid-resistant or intolerant patients: use cyclosporine 3-5 mg/kg/day or tacrolimus 0.05-0.1 mg/kg/day 2
- For frequently relapsing disease: oral cyclophosphamide 2-2.5 mg/kg/day for 8 weeks, or CNIs for 1-2 years 2
For Focal Segmental Glomerulosclerosis
- Immunosuppression only indicated if nephrotic-range proteinuria is present 2, 3
- Same steroid regimen as MCD: prednisone 1 mg/kg/day for minimum 4 weeks, up to 16 weeks maximum 3, 2
- Adults respond much slower than children; >50% remain steroid-resistant 3
- For steroid-resistant FSGS: cyclosporine 3-5 mg/kg/day for at least 4-6 months 2
- If partial/complete remission occurs, continue cyclosporine for at least 12 months, then slow taper 2
- Alternative for steroid-resistant: mycophenolate mofetil plus high-dose dexamethasone (33% remission rate) 3
Critical caveat: Distinguish idiopathic from secondary FSGS (due to reduced glomerular mass, obesity, hypertension). Secondary FSGS should NOT receive immunosuppression—only cardiovascular risk reduction 3.
Management of Edema
Sodium restriction to <2.0 g/day is foundational 4. This is synergistic with all other interventions.
Diuretic Strategy 4:
- Start with loop diuretics (furosemide or bumetanide)
- If inadequate response, add thiazide diuretic for sequential nephron blockade
- Consider adding potassium-sparing diuretic (amiloride or spironolactone) to prevent hypokalemia and enhance diuresis
- For refractory edema with low GFR: consider intravenous albumin followed by intravenous loop diuretic
- Acetazolamide may help metabolic alkalosis but is weak diuretic
Monitor for diuretic resistance, which occurs commonly in nephrotic syndrome due to urinary protein binding of diuretics 4.
Management of Proteinuria and Hypertension
ACE inhibitors or ARBs are first-line therapy for both hypertension and proteinuria reduction 4.
Key Implementation Points 4:
- Uptitrate to maximally tolerated dose
- Target systolic blood pressure <120 mmHg (using standardized office measurement)
- Do not stop if creatinine rises up to 30% (unless progressive worsening or refractory hyperkalemia)
- Critical warning: Do NOT start ACEi/ARB in patients with abrupt-onset nephrotic syndrome, especially MCD, as this can cause acute kidney injury 4
- Consider delaying ACEi/ARB in podocytopathies expected to respond rapidly to immunosuppression 4
Managing Hyperkalemia to Allow RAS Blockade 4:
- Use potassium-wasting diuretics
- Use potassium-binding agents
- Treat metabolic acidosis (target bicarbonate >22 mmol/L)
- Consider mineralocorticoid receptor antagonists for refractory proteinuria (monitor potassium closely)
Sick Day Rules 5, 4:
Counsel patients to hold ACEi/ARB and diuretics during volume depletion (vomiting, diarrhea, excessive sweating, inadequate fluid intake) to prevent hemodynamic acute kidney injury.
Important note: Dihydropyridine calcium channel blockers (amlodipine, nifedipine) exacerbate edema and may increase proteinuria—avoid or discontinue if proteinuria worsens 5.
Management of Hyperlipidemia
Statins are first-line therapy for persistent hyperlipidemia 4, particularly in patients with:
- Other cardiovascular risk factors (hypertension, diabetes)
- Target LDL-cholesterol <100 mg/dL (2.58 mmol/L) 6
The risk of coronary heart disease is four times greater in nephrotic patients compared to age-matched controls 1. However, for initial episodes of MCD, statins are not recommended until proteinuria persists beyond initial treatment 2.
Thromboembolism Prevention
Nephrotic syndrome carries dramatically elevated thrombotic risk: 29% renal vein thrombosis, 17-28% pulmonary embolism, 11% deep vein thrombosis in membranous nephropathy 1.
Anticoagulation Indications 6, 7:
- Consider anticoagulation when serum albumin <20 g/L (2.0 g/dL), especially if:
- Persistent nephrotic syndrome
- Presence of antiphospholipid antibodies
- Membranous nephropathy
Recent evidence suggests eight-fold increased risk of venous thromboembolism, with albumin <2.5 g/dL being a key threshold 8.
Additional Supportive Measures
Infection Prevention 1:
- Pneumococcal vaccination (children at particular risk for cellulitis and spontaneous bacterial peritonitis)
- Immunizations with non-live vaccines 6
Hydroxychloroquine (for Lupus Nephritis) 6:
- Recommended to reduce renal flares and limit accrual of renal and cardiovascular damage
Monitoring Parameters 1, 6:
Complete remission is defined as:
- Adults: Proteinuria <0.20 g/day and serum albumin >35 g/L
- Children: Proteinuria <4 mg/m²/h on 3 occasions within 7 days and serum albumin >35 g/L
Partial remission (adults): Proteinuria 0.21-3.4 g/day AND >50% reduction from baseline 1
Critical Prognostic Information
Proteinuria >3.8 g/day carries 35% risk of ESRD within 2 years (versus 4% risk if <2.0 g/day) 1. Each 1.0 g/dL decrease in serum albumin increases morbidity odds by 89% and mortality by 137% 1. Therefore, the primary treatment objective is lowering proteinuria while balancing therapy risks 1.
The response of proteinuria to therapy is the main predictor of prognosis across all histologic variants 1.